Taiyen Biotech Co., Ltd. (TPE:1737)
Taiwan
· Delayed Price · Currency is TWD 31.80
+0.10 (0.32%)
Apr 29, 2026, 1:30 PM CST
Taiyen Biotech Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 3,308 | 3,238 | 3,409 | 3,614 | 4,096 | Upgrade
|
| Revenue Growth (YoY) | 2.15% | -5.01% | -5.67% | -11.77% | 30.84% | Upgrade
|
| Cost of Revenue | 1,965 | 1,917 | 2,151 | 2,337 | 2,722 | Upgrade
|
| Gross Profit | 1,341 | 1,321 | 1,257 | 1,277 | 1,373 | Upgrade
|
| Selling, General & Admin | 821.75 | 835.39 | 801.98 | 770.92 | 786.46 | Upgrade
|
| Research & Development | 54.78 | 54.71 | 60.5 | 60.64 | 57.6 | Upgrade
|
| Operating Expenses | 866.87 | 966.37 | 936.04 | 831.56 | 844.06 | Upgrade
|
| Operating Income | 474.19 | 354.54 | 321.44 | 445.05 | 529.18 | Upgrade
|
| Interest Expense | -3.72 | -6.34 | -3.35 | -4.52 | -5.94 | Upgrade
|
| Interest & Investment Income | 26.35 | 37.93 | 35.93 | 17.88 | 10.66 | Upgrade
|
| Currency Exchange Gain (Loss) | -16.74 | 38.54 | -5.67 | 58.69 | -20.59 | Upgrade
|
| Other Non Operating Income (Expenses) | 29.31 | 2.99 | -21.26 | 20.65 | 1.93 | Upgrade
|
| EBT Excluding Unusual Items | 509.38 | 427.66 | 327.1 | 537.74 | 515.23 | Upgrade
|
| Gain (Loss) on Sale of Investments | 7.61 | 12.85 | 7.43 | -0.36 | -0.54 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.48 | -1.04 | -1.28 | -1.28 | -1.24 | Upgrade
|
| Other Unusual Items | -22.54 | -6.44 | -4.13 | -5.52 | -3.54 | Upgrade
|
| Pretax Income | 493.97 | 433.03 | 329.12 | 530.59 | 509.92 | Upgrade
|
| Income Tax Expense | 100.28 | 115.58 | 111.82 | 103.07 | 97.76 | Upgrade
|
| Earnings From Continuing Operations | 393.69 | 317.45 | 217.3 | 427.52 | 412.16 | Upgrade
|
| Minority Interest in Earnings | 6.18 | 54.07 | 83.09 | -0.81 | -18.94 | Upgrade
|
| Net Income | 399.87 | 371.52 | 300.39 | 426.7 | 393.23 | Upgrade
|
| Net Income to Common | 399.87 | 371.52 | 300.39 | 426.7 | 393.23 | Upgrade
|
| Net Income Growth | 7.63% | 23.68% | -29.60% | 8.51% | 7.71% | Upgrade
|
| Shares Outstanding (Basic) | 200 | 200 | 200 | 200 | 200 | Upgrade
|
| Shares Outstanding (Diluted) | 201 | 201 | 200 | 201 | 201 | Upgrade
|
| Shares Change (YoY) | 0.04% | 0.06% | -0.08% | 0.05% | - | Upgrade
|
| EPS (Basic) | 2.00 | 1.86 | 1.50 | 2.13 | 1.97 | Upgrade
|
| EPS (Diluted) | 1.99 | 1.85 | 1.50 | 2.13 | 1.96 | Upgrade
|
| EPS Growth | 7.57% | 23.33% | -29.58% | 8.67% | 7.69% | Upgrade
|
| Free Cash Flow | 131.89 | 352.51 | 112.89 | 334.58 | 211.29 | Upgrade
|
| Free Cash Flow Per Share | 0.66 | 1.76 | 0.56 | 1.67 | 1.05 | Upgrade
|
| Dividend Per Share | 1.400 | 1.300 | 1.200 | 1.500 | 1.500 | Upgrade
|
| Dividend Growth | 7.69% | 8.33% | -20.00% | - | 11.11% | Upgrade
|
| Gross Margin | 40.54% | 40.79% | 36.89% | 35.33% | 33.53% | Upgrade
|
| Operating Margin | 14.34% | 10.95% | 9.43% | 12.32% | 12.92% | Upgrade
|
| Profit Margin | 12.09% | 11.47% | 8.81% | 11.81% | 9.60% | Upgrade
|
| Free Cash Flow Margin | 3.99% | 10.89% | 3.31% | 9.26% | 5.16% | Upgrade
|
| EBITDA | 710.17 | 561.57 | 508.88 | 628.74 | 707.81 | Upgrade
|
| EBITDA Margin | 21.47% | 17.34% | 14.93% | 17.40% | 17.28% | Upgrade
|
| D&A For EBITDA | 235.98 | 207.03 | 187.44 | 183.69 | 178.64 | Upgrade
|
| EBIT | 474.19 | 354.54 | 321.44 | 445.05 | 529.18 | Upgrade
|
| EBIT Margin | 14.34% | 10.95% | 9.43% | 12.32% | 12.92% | Upgrade
|
| Effective Tax Rate | 20.30% | 26.69% | 33.98% | 19.43% | 19.17% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.